Know Labs Provides Update on its Intellectual Property Portfolio
Know Labs (OTC: KNWND), a leader in Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology, has announced updates to its intellectual property portfolio. The company currently holds 325 patents (issued, pending, and in process) and has revealed a library of 1,022 trade secrets codified through the Tangibly platform.
According to an independent analysis by PatSnap, Know Labs' patent portfolio ranks first globally in specific categories of medical diagnostics and industrial process control. The company's IP strategy involves both patents and trade secrets, with the latter being disclosed publicly for the first time as part of their Know Labs Technology Licensing (KTL) initiative.
The slight reduction from previously reported 332 patent assets is attributed to combining provisional patents into utility patents and strategic abandonment of less critical pending patents. The company emphasizes that both patents and trade secrets will continue to grow as innovation progresses.
Know Labs (OTC: KNWND), leader nella tecnologia dei sensori di Spettroscopia Dielettrica a Radio Frequenza (RFDS), ha annunciato aggiornamenti al suo portafoglio di proprietà intellettuale. L'azienda detiene attualmente 325 brevetti (emessi, in attesa e in fase di elaborazione) e ha rivelato una biblioteca di 1.022 segreti commerciali codificati attraverso la piattaforma Tangibly.
Secondo un'analisi indipendente di PatSnap, il portafoglio di brevetti di Know Labs si posiziona al primo posto a livello globale in specifiche categorie di diagnostica medica e controllo dei processi industriali. La strategia di proprietà intellettuale dell'azienda comprende sia brevetti che segreti commerciali, con questi ultimi resi pubblici per la prima volta come parte della loro iniziativa Know Labs Technology Licensing (KTL).
La lieve riduzione rispetto ai 332 beni brevettuali precedentemente riportati è attribuita alla combinazione di brevetti provvisori in brevetti di utilità e all'abbandono strategico di brevetti in attesa meno critici. L'azienda sottolinea che sia i brevetti che i segreti commerciali continueranno a crescere con il progresso dell'innovazione.
Know Labs (OTC: KNWND), líder en tecnología de sensores de Espectroscopía Dielectrica de Radiofrecuencia (RFDS), ha anunciado actualizaciones a su cartera de propiedad intelectual. La empresa actualmente posee 325 patentes (emitidas, pendientes y en proceso) y ha revelado una biblioteca de 1,022 secretos comerciales codificados a través de la plataforma Tangibly.
Según un análisis independiente de PatSnap, la cartera de patentes de Know Labs ocupa el primer lugar a nivel mundial en categorías específicas de diagnóstico médico y control de procesos industriales. La estrategia de propiedad intelectual de la empresa involucra tanto patentes como secretos comerciales, siendo estos últimos divulgados públicamente por primera vez como parte de su iniciativa Know Labs Technology Licensing (KTL).
La ligera reducción de los 332 activos de patentes reportados anteriormente se atribuye a la combinación de patentes provisionales en patentes de utilidad y al abandono estratégico de patentes pendientes menos críticas. La empresa enfatiza que tanto las patentes como los secretos comerciales seguirán creciendo a medida que avance la innovación.
Know Labs (OTC: KNWND)는 전파 주파수 유전 분광법(RFDS) 센서 기술의 선두주자로서 지적 재산 포트폴리오에 대한 업데이트를 발표했습니다. 현재 이 회사는 325개의 특허 (발급, 대기 중 및 진행 중)를 보유하고 있으며, Tangibly 플랫폼을 통해 1,022개의 영업 비밀 라이브러리를 공개했습니다.
PatSnap의 독립 분석에 따르면 Know Labs의 특허 포트폴리오는 의료 진단 및 산업 공정 제어의 특정 범주에서 전 세계적으로 1위를 차지하고 있습니다. 회사의 지적 재산 전략은 특허와 영업 비밀 모두를 포함하며, 후자는 Know Labs 기술 라이센스(KTL) 이니셔티브의 일환으로 처음으로 공개되었습니다.
이전 보고된 332개의 특허 자산에서의 약간의 감소는 임시 특허를 유틸리티 특허로 통합하고 덜 중요한 대기 특허를 전략적으로 포기한 데 기인합니다. 회사는 혁신이 진행됨에 따라 특허와 영업 비밀 모두 계속 성장할 것이라고 강조합니다.
Know Labs (OTC: KNWND), un leader dans la technologie des capteurs de Spectroscopie Diélectrique par Radiofréquence (RFDS), a annoncé des mises à jour de son portefeuille de propriété intellectuelle. L'entreprise détient actuellement 325 brevets (délivrés, en attente et en cours) et a révélé une bibliothèque de 1.022 secrets commerciaux codifiés via la plateforme Tangibly.
Selon une analyse indépendante de PatSnap, le portefeuille de brevets de Know Labs se classe au premier rang mondial dans des catégories spécifiques de diagnostics médicaux et de contrôle des processus industriels. La stratégie de propriété intellectuelle de l'entreprise implique à la fois des brevets et des secrets commerciaux, ces derniers étant divulgués publiquement pour la première fois dans le cadre de leur initiative Know Labs Technology Licensing (KTL).
La légère réduction par rapport aux 332 actifs de brevets précédemment rapportés est attribuée à la combinaison de brevets provisoires en brevets d'utilité et à l'abandon stratégique de brevets en attente moins critiques. L'entreprise souligne que les brevets et les secrets commerciaux continueront à croître à mesure que l'innovation progresse.
Know Labs (OTC: KNWND), ein führendes Unternehmen in der Technologie der Radiofrequenz-Dielektrik-Spektroskopie (RFDS) Sensoren, hat Aktualisierungen seines Portfolios an geistigem Eigentum angekündigt. Das Unternehmen hält derzeit 325 Patente (erteilt, anhängig und in Bearbeitung) und hat eine Bibliothek von 1.022 Geschäftsgeheimnissen veröffentlicht, die über die Tangibly-Plattform kodifiziert sind.
Nach einer unabhängigen Analyse von PatSnap belegt das Patentportfolio von Know Labs weltweit den ersten Platz in bestimmten Kategorien der medizinischen Diagnostik und der industriellen Prozesskontrolle. Die IP-Strategie des Unternehmens umfasst sowohl Patente als auch Geschäftsgeheimnisse, wobei letztere im Rahmen ihrer Know Labs Technology Licensing (KTL)-Initiative erstmals öffentlich gemacht wurden.
Die leichte Reduzierung von zuvor gemeldeten 332 Patentvermögen wird auf die Kombination von vorläufigen Patenten in Gebrauchsmuster und die strategische Aufgabe weniger kritischer anhängiger Patente zurückgeführt. Das Unternehmen betont, dass sowohl Patente als auch Geschäftsgeheimnisse weiter wachsen werden, während die Innovation voranschreitet.
- Ranks #1 globally in certain medical diagnostics and industrial process control patent categories
- Substantial IP portfolio with 325 patents and 1,022 trade secrets
- New licensing initiative (KTL) opens additional revenue opportunities
- Reduction in patent assets from 332 to 325
325 Patents (Issued, Pending and In Process) and 1,022 Trade Secrets
An independent third-party analysis by PatSnap www.patsnap.com has reported that in certain categories of medical diagnostics and industrial process control, the Know Labs patent portfolio ranks Number One in the world. Their analysis does not, of course, cover our trade secret portfolio, as its detail remains confidential and undisclosed.
A foundational aspect of Know Labs focus since its inception has been the protection of its prolific innovation through the filing of patents and the rigorous guarding of its trade secrets. For context, patents and trade secrets are two distinct forms of intellectual property protection that businesses and inventors can use to safeguard their innovations. Each has its unique characteristics, advantages, and disadvantages, making them suitable for different situations:
Patents
A patent is a legal right granted by a government authority to an inventor or assignee for a new, useful, and non-obvious invention. This right gives the patent holder the exclusive right to make, use, sell, and import the invention for a limited period, typically 20 years from the filing date. To obtain a patent, the inventor must publicly disclose the details of the invention in a patent application, which is then examined by a patent office.
Trade Secrets
A trade secret is any confidential business information that provides a competitive edge. Unlike patents, trade secrets do not require registration or disclosure to a government authority. Instead, protection is maintained through secrecy measures, such as non-disclosure agreements and internal security protocols. Trade secrets remain protected as long as they remain confidential and provide economic value to the holder.
The total list of issued, pending and in process patents is slightly lower today than previously reported 332 active patent assets. That is a result of combining provisional patents into a single utility patent and the abandonment of pending patents deemed unimportant by the Company as it right sized all its activities, including its IP protection efforts. Both Company patents and trade secrets will grow in number over time as innovation continues. Today is the first time the Company has publicly announced the total number of its codified trade secrets. This announcement is necessitated by the work underway with various third parties through our recently initiated Know Labs Technology Licensing (KTL)
“We have built Know Labs intellectual property portfolio in a very strategic manner.,” said Pete Conley, Know Labs Chief Financial Officer and Senior Vice President Intellectual Property, “Built upon the foundation of our inventions which are grounded on immutable 'first principles' of physics, we have created a world class patent portfolio that covers core elements of how our technology works and a myriad of applications across diverse industries and a wide range of fields of use. We have designed the patent portfolio to both protect our inventions and to work in a collaborative way with potential partners in medical diagnostics, industrial applications and beyond. We view our trade secrets, codified through Tangibly, as a fundamental cornerstone of a complete intellectual property (IP) portfolio; as such, we are now disclosing our trade secret assets as a significant addition to our IP portfolio. With KTL now formally launched, Know Labs is open for the business of licensing the intellectual property associated with its broad platform technology.”
About Know Labs Technology Licensing (KTL)
Know Labs Technology Licensing (KTL) is the dedicated licensing division of Know Labs, Inc. (OTC: KNWN), facilitating the global adoption of its patented Radio Frequency Dielectric Spectroscopy (RFDS) technology. With an extensive intellectual property portfolio, a structured licensing framework, and the proprietary e-RFDS© digital watermark, KTL enables corporations, universities, and research institutions to innovate with confidence while securing their developments from counterfeiting and unauthorized use.
About Know Labs, Inc.
Know Labs, Inc.’s platform technology uses radio frequency dielectric spectroscopy (RFDS) to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. Among the Company’s first expected applications of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226423411/en/
Know Labs, Inc. Contact:
Investor Relations
T: 206-903-1351
ask@knowlabs.co
Source: Know Labs, Inc.
FAQ
How many patents and trade secrets does Know Labs (KNWND) currently hold?
What is Know Labs (KNWND) global ranking in medical diagnostics patents?
Why did Know Labs (KNWND) patent portfolio decrease from 332 to 325 assets?
What is the purpose of Know Labs Technology Licensing (KTL) initiative?
